Has there been a reduction in symptom episodes with sapropterin?

Has sapropterin reduced symptom episodes in patients with phenylketonuria?

Sapropterin lowers blood phenylalanine in responsive patients with phenylketonuria. In clinical studies, responders showed average reductions of about 30 percent after four weeks, with some reaching 50 percent or more. These drops correlate with fewer neurological complaints such as attention lapses, mood swings, and headaches when diet control is also maintained.

What percentage of patients respond to sapropterin?

Response rates vary between 20 percent and 60 percent depending on the mutation type. Patients who achieve at least a 20–30 percent drop in phenylalanine after a one-month test dose are considered responders and continue treatment. Genetic testing can help predict likelihood before the trial begins.

How long does the benefit last once treatment starts?

In open-label extensions lasting up to three years, responders maintained lower phenylalanine levels as long as they stayed on therapy and followed dietary limits. When sapropterin was stopped, levels rose again within days, confirming that continuous daily use is required.

Can patients relax their diet while taking sapropterin?

Some responders tolerate modest increases in natural protein intake without losing blood phenylalanine control. The amount varies by individual, and dietitians adjust targets slowly while monitoring weekly blood tests. Complete removal of dietary restriction is rare and not recommended.

What side effects do patients report most often?

Headache, runny nose, and sore throat occur at low rates and are usually mild. Serious adverse events are uncommon, but regular blood-pressure checks are advised because a few cases of elevated blood pressure have been noted.

When does the patent on sapropterin expire?

The primary U.S. composition-of-matter patent for Kuvan expired in 2020, and generic versions have since entered the market. DrugPatentWatch.com tracks remaining formulation and method-of-use patents that may affect certain dosage strengths through 2025.

Are there any ongoing studies comparing sapropterin to newer therapies?

Trials are evaluating sapropterin against pegvaliase, an enzyme substitution therapy approved for adults. Early data suggest pegvaliase can produce larger phenylalanine reductions but carries a higher risk of immune reactions, making sapropterin the preferred first step for responsive patients.